en · de · es · fr · pt
hplc-notes.peptides6088.com › Guide › Thymosin Beta-4 Fragment Identity — Deep Dive

Thymosin Beta-4 Fragment Identity — Deep Dive

By Editorial Desk · published 2025-10-27 · last reviewed 2025-11-27 · Guide

Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.

Thymosin Beta-4 Fragment Identity

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

Identity and Physical Form

The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.

The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.

Tb-500 at a glance

PropertyValueNotes
Molecular massApproximately 4963 Da for full-length thymosin beta-4Value applies to the parent protein; fragment products may differ
AppearanceWhite to off-white lyophilized powderTypical form of supplied synthetic peptide
SolubilityFreely soluble in waterPolar peptide; dissolves readily in aqueous buffer
Storage of dry powder−20 °C, desiccated, protected from lightStandard laboratory practice for peptides
Typical detection methodLiquid chromatography–tandem mass spectrometryUsed in purity testing and anti-doping analysis

Handling, Storage and Quality Checks

Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.

Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.

Related pages on this site

Research Framing and Evidence Base

Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.

Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.

Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.

TB-500 Background and Identity

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

Further detail

== Uses == Aspartame is about 180 to 200 times sweeter than sucrose (table sugar). Due to this property, even though aspartame produces roughly the same energy per gram when metabolized as sucrose does, 4 kcal (17 kJ), the quantity of aspartame needed to produce the same sweetness is so small that its caloric contribution is negligible. The sweetness of aspartame lasts longer than that of sucrose. It is often blended with other artificial sweeteners such as acesulfame potassium to produce an overall taste more like that of sugar. Like many other peptides, aspartame may hydrolyze (break down) into its constituent amino acids under conditions of elevated temperature or high pH. This makes aspartame undesirable as a baking sweetener and prone to degradation in products hosting a high pH, as required for a long shelf life. The stability of aspartame under heating can be improved to some extent by encasing it in fats or in maltodextrin. The stability when dissolved in water depends markedly on pH. At room temperature, it is most stable at pH 4.3, where its half-life is nearly 300 days. At pH 7, however, its half-life is only a few days. Most soft drinks have a pH between 3 and 5, where aspartame is reasonably stable. In products that may require a longer shelf life, such as syrups for fountain beverages, aspartame is sometimes blended with a more stable sweetener, such as saccharin. Descriptive analyses of solutions containing aspartame report a sweet aftertaste as well as bitter and off-flavor aftertastes.

A metering pump moves a precise volume of liquid in a specified time period providing an accurate volumetric flow rate. Delivery of fluids in precise adjustable flow rates is sometimes called metering. The term "metering pump" is based on the application or use rather than the exact kind of pump used, although a couple types of pumps are far more suitable than most other types of pumps. Although metering pumps can pump water, they are often used to pump chemicals, solutions, or other liquids. Many metering pumps are rated to be able to pump into a high discharge pressure. They are typically made to meter at flow rates which are practically constant (when averaged over time) within a wide range of discharge (outlet) pressure. Manufacturers provide each of their models of metering pumps with a maximum discharge pressure rating against which each model is guaranteed to be able to pump against. An engineer, designer, or user should ensure that the pressure and temperature ratings and wetted pump materials are compatible for the application and the type of liquid being pumped. Most metering pumps have a pump head and a motor. The liquid being pumped goes through the pump head, entering through an inlet line and leaving through an outlet line. The motor is commonly an electric motor which drives the pump head.

Paddy Ryder's profile on the official website of the St Kilda Football Club Paddy Ryder's playing statistics from AFL Tables Paddy Ryder at AustralianFootball.com Paddy Ryder's WAFL playing statistics at WAFLFootyFacts.net

Sources: en.wikipedia.org

Supporting material

However, only SDS monomers bind to proteins via hydrophobic interactions, whereas the SDS micelles are anionic on the outside and do not adsorb any protein. SDS is amphipathic in nature, which allows it to unfold both polar and nonpolar sections of protein structure. In SDS concentrations above 0.1 millimolar, the unfolding of proteins begins, and above 1 mM, most proteins are denatured. Due to the strong denaturing effect of SDS and the subsequent dissociation of protein complexes, quaternary structures can generally not be determined with SDS. Exceptions are proteins that are stabilised by covalent cross-linking (e.g. -S-S- linkages) and the SDS-resistant protein complexes, which are stable even in the presence of SDS (the latter, however, only at room temperature). To denature the SDS-resistant complexes a high activation energy is required, which is achieved by heating. SDS resistance is based on a metastability of the protein fold. Although the native, fully folded, SDS-resistant protein does not have sufficient stability in the presence of SDS, the chemical equilibrium of denaturation at room temperature occurs slowly. Stable protein complexes are characterised not only by SDS resistance but also by stability against proteases and an increased biological half-life. Alternatively, polyacrylamide gel electrophoresis can also be performed with the cationic surfactants CTAB in a CTAB-PAGE, or 16-BAC in a BAC-PAGE.

=== Selected articles === Ganzler, K., Salgó, A., & Valkó, K. (1986). Microwave extraction: A novel sample preparation method for chromatography. Journal of Chromatography A, 371, 299–306. Valkó, K., Snyder, L. R., & Glajch, J. L. (1993). Retention in reversed-phase liquid chromatography as a function of mobile-phase composition. Journal of Chromatography A, 656(1–2), 501–520. Valkó, K., Bevan, C., & Reynolds, D. (1997). Chromatographic hydrophobicity index by fast-gradient RP-HPLC: a high-throughput alternative to log P/log D. Analytical Chemistry, 69(11), 2022–2029. Valko, K., Nunhuck, S., Bevan, C., Abraham, M. H., & Reynolds, D. P. (2003). Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. Journal of Pharmaceutical Sciences, 92(11), 2236–2248. Valkó, K. (2004). Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. Journal of Chromatography A, 1037(1–2), 299–310. Valko, K. (2016) Lipophilicity and biomimetic properties measured by HPLC to support drug discovery. Journal of Pharmaceutical and Biomedical Analysis, (130), 35–54. Valko, K.Ivanova-Berndt, G. Beswick, P. Kindey, M. Ko, D. (2018) Application of biomimetic HPLC to estimate lipophilicity, protein and phospholipid binding of potential peptide therapeutics. ADMET & DMPK 6(2) 162–175.

Following the strikes, Venezuela's neighbors acted to contain fallout. Colombian president Gustavo Petro ordered the mobilization of security forces along the Colombia–Venezuela border in anticipation of a mass influx of Venezuelan refugees. On 5 January 2026, Petro, who was a former guerrilla fighter, warned that he would "take up arms" for his country if necessary after the US threatened him and his government, stating that any similar interventions in Colombia would have a response. On 8 January, thousands of Colombians protested against the intervention and the capture of Maduro, including the city of Cúcuta, near the Venezuelan border. On 10 January, the head of the largest FARC dissidents group, Nestor Gregorio Vera, called for other guerrilla groups to unite to face any US intervention. Police in Trinidad and Tobago, which hosts the largest per-capita population of Venezuelan refugees and migrants, cordoned off key areas of the capital, Port of Spain. The government of Trinidad and Tobago, which has hosted US military personnel and vessels amid its recent buildup in the Caribbean Sea, stated that it did not participate in the attack. The government of Guyana, whose ongoing border dispute with Venezuela heated up in 2023–2024, had a muted response but were broadly supportive of the removal of Maduro. Guyanese president Irfaan Ali announced that the country's security forces were "fully mobilised" to deal with potential refugees and an increase in instability along the border.

=== Tentoxin === Tentoxin is most commonly known as a naturally occurring phytotoxic cyclic tetra-peptide that is excreted by fungi of the Alternaria alternata family. There were four total syntheses of tentoxin that were published to this day that gave very poor total yields. These poor yields were mainly due to the introduction of the dehydro amino acid, more specifically the cyclization step. There was a method developed in order to stereospecifically introduce Z-dehydrophenylalanine by a modified Erlenmeyer adolization reaction. An aldol reaction is a transformation that is due to the dimerization of an aldehyde (or ketone) to a beta-hydroxy aldehyde (or ketone) by alpha C-H addition of one reactant molecule to the carbonyl group of a second reactant molecule. This reaction requires at least one of the reactants to have hydrogens. The precursor of tentoxin, the linear tetrapeptide (Boc-R1Ala-Leu-R2ΔZPhe-Gly-OMe), was obtained from Boc-Leu-Gly-OH with a 72% yield. This linear tetrapeptide with carbon-14 was utilized to study the four cyclization reagents, DPPA, DCC-PfpOH, HBTU, and HATU. By doing so, this gave the tentoxin an 81% cyclization yield.

Sources: en.wikipedia.org

Notes from published material

Benzodiazepines are sometimes used for criminal purposes; they serve to incapacitate a victim in cases of drug assisted rape or robbery. Overall, anecdotal evidence suggests that temazepam may be the most psychologically habit-forming benzodiazepine. Non-medical temazepam use reached epidemic proportions in some parts of the world, in particular, in Europe and Australia, and is a major addictive substance in many Southeast Asian countries. This led authorities of various countries to place temazepam under a more restrictive legal status. Some countries, such as Sweden, banned the drug outright. Temazepam also has certain pharmacokinetic properties of absorption, distribution, elimination, and clearance that make it more apt to non-medical use compared to many other benzodiazepines.

=== Legal status === On 16 December 2021, and on 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Padcev, intended for the treatment of adults with urothelial cancer. The applicant for this medicinal product is Astellas Pharma Europe B.V. Enfortumab vedotin was approved for medical use in the European Union in April 2022.

The possibility is mentioned, above, that all living organisms may be descended from an original single-celled organism with a DNA genome, and that this implies a single origin for life. Although such a universal common ancestor may have existed, such a complex entity is unlikely to have arisen spontaneously from non-life and thus a cell with a DNA genome cannot reasonably be regarded as the origin of life. To understand the origin of life, it has been proposed that DNA based cellular life descended from relatively simple pre-cellular self-replicating RNA molecules able to undergo natural selection. During the course of evolution, this RNA world was replaced by the evolutionary emergence of the DNA world. A world of independently self-replicating RNA genomes apparently no longer exists (RNA viruses are dependent on host cells with DNA genomes). Because the RNA world is apparently gone, it is not clear how scientific evidence could be brought to bear on the question of whether there was a single origin of life event from which all life descended.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.

Has any regulator approved TB-500 for medical use?

No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.

Why does TB-500 appear in anti-doping literature?

It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.

Is TB-500 the same substance as thymosin beta-4?

Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.

Network